ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMRX vs ABEO // RSI-14 & 200D SMA MOMENTUM

Immuneering Corporation (Class A) (NASDAQ) VS. Abeona Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IMRX 1 — ABEO 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: IMRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMRX VS. ABEO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMRX ABEO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 73.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -17.49% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 52.6 43.7 +8.90 IMRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.1M $260.8M -$675.6K ABEO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMRX REV ABEO REV IMRX GROSS % ABEO GROSS % IMRX FCF ABEO FCF
FY 2025 $0 $5.8M — 73.7% -$45.5M -$84.3M
FY 2024 $0 $0 — — -$55.1M -$58.5M
FY 2023 $0 $3.5M — — -$49.0M -$37.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMRX // BETA —
ABEO // BETA —